{"nctId":"NCT00525044","briefTitle":"Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat","startDateStruct":{"date":"2007-08-01","type":"ACTUAL"},"conditions":["Pharyngitis"],"count":249,"armGroups":[{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ambroxol","type":"EXPERIMENTAL","interventionNames":["Drug: Ambroxol"]}],"interventions":[{"name":"Ambroxol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"1\\. Patients having a sore throat with acute viral pharyngitis. 2. Female and male ambulant patients between the ages of 18 and 65. 3. The throat pain intensity is rated at least severe on the VRS (PI). 4. Written Informed Consent is given by the patient. 5. Compliance by the patient seems guaranteed.\n\n1. Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection (clinical findings; inter alia assessment of exudate).\n2. First indication of symptoms of acute pharyngitis (e.g., sore throat) occurred more than 3 days ago already.\n3. Counting of white blood cell in blood routine examination exceeds 10?109/L.\n4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.\n5. Broncho-motor disorders or concomitant diseases with relatively large quantities of secretion (danger of secretion blockage).\n6. Known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet.\n7. Previous and/or existing tumour condition.\n8. Pregnancy and/or breast-feeding.\n9. Alcohol, and/or drug abuse.\n10. Simultaneous participation in another clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline","description":"The calculation will be based on the pain intensity (PI) assessment by the patient before and then at (pain intensity difference at 30 minutes (PID30)), (pain intensity difference at 60 minutes (PID60)), (pain intensity difference at 120 minutes (PID120)) and (pain intensity difference at 180 minutes (PID180)) after the 1st lozenge. Using the difference in PI from pre-dose baseline for each time point subsequent to dosing, the SPIDnorm will be calculated as SPIDnorm = (30\\*PID30 + 30\\*PID60 + 60\\*PID120 + 60\\*PID180)/(180\\*PI (baseline)) The patient rates the intensity of his sore throat pain on a 6-point Verbal Rating Scale (VRS) pain intensity (PI) before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.020"},{"groupId":"OG001","value":"-0.34","spread":"0.020"}]}]}]},{"type":"SECONDARY","title":"Pain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge","description":"Pain intensity (PI) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge.\n\nThe patient rates the intensity of his sore throat condition on a 6-point rating scale \\[VRS(PI)-verbal rating scale (pain intensity)\\] before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.\n\nAdjusted Mean (Standard Error) are presented for this outcome measure.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.08"},{"groupId":"OG001","value":"3.1","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"0.08"},{"groupId":"OG001","value":"2.8","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.10"},{"groupId":"OG001","value":"2.7","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.10"},{"groupId":"OG001","value":"2.5","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Pain Intensity Difference From Pre-dose Baseline (PID) as Rated on a 6-point Verbal Rating Scale (VRS) by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge","description":"Pain intensity difference from pre-dose baseline (PID) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge.\n\nAdjusted Mean (Standard Error) are presented for this outcome measure.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.08"},{"groupId":"OG001","value":"-1.0","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"0.08"},{"groupId":"OG001","value":"-1.2","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.10"},{"groupId":"OG001","value":"-1.4","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.10"},{"groupId":"OG001","value":"-1.6","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Assessment of Redness of the Pharyngeal Mucosa by the Investigator on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation","description":"Assessment of redness of the pharyngeal mucosa by the investigator on a 5-point VRS (normal, slightly red, clearly red, very red, severe inflammation) at pre-dose baseline and at the end-of-study evaluation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"12.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","spread":null},{"groupId":"OG001","value":"50.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Patients' Assessment of Effectiveness on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation","description":"Assessment of Patients' Assessment of Effectiveness on a 5-point VRS (\"very good\", \"good\", \"neither good nor poor\", \"not very good\", \"not at all good\") at pre-dose baseline and at the end-of-study evaluation","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"52.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":[]}}}